Table 3.
Screening outcomes by the infecting human papillomavirus (HPV) genotype in three laboratories that managed women according to genotype at 12 month early recall
| Outcome | HPV 16/18 | Other HPV | Odds rato for HPV 16/18 v other HPV (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
| No (%) | Total | No (%) | Total | Unadjusted | Adjusted | |||
| No at baseline | ||||||||
| Screened | 5207 (4) | 127 238 | 10 890 (9) | 127 238 | NA | NA | ||
| Positive cytology | 2293 (44) | 5207 | 2994 (27) | 10 890 | 2.08 (1.94 to 2.22) | 2.02 (1.89 to 2.17) | ||
| Persistence of hrHPV infection | ||||||||
| Negative cytology at baseline, persistence at 12 months | 1639 (68) | 2398 | 3624 (55) | 6566 | 1.75 (1.58 to 1.93) | 1.72 (1.56 to 1.90)* | ||
| Negative cytology at 12 months, persistence at 24 months | NA | NA | 1368 (65) | 2091 | NA | NA | ||
| Colposcopy outcomes | ||||||||
| PPV for CIN2+ at baseline, positive cytology | 1295 (57) | 2254 | 840 (29) | 2909 | 3.33 (2.96 to 3.73) | 3.12 (2.78 to 3.52) | ||
| PPV for CIN2+ at 12 months, positive cytology | 252 (48) | 528 | 221 (27) | 825 | 2.50 (1.98 to 3.14) | 2.28 (1.80 to 2.89) | ||
| PPV for CIN2+ at 12 months, negative cytology | 103 (13) | 789 | NA | NA | NA | NA | ||
| PPV for CIN2+ at 24 months, persistent hrHPV+ | NA | NA | 117 (10) | 1144 | NA | NA | ||
See supplementary figure 1A for hrHPV testing details.
NA=not applicable; hrHPV=high risk human papillomavirus; PPV=positive predictive value; CIN2+= cervical intraepithelial neoplasia grade 2 or worse.
*
For clearance (=1-persistence), the unadjusted odds ratio was 0.57 (95% CI 0.52 to 0.63), and the adjusted odds ratio was 0.58 (95% CI 0.53 to 0.64).